30Jul 2024
FDA Approves Guardant Health's Blood-Based Cancer Test

FDA Approves Guardant Health's Blood-Based Cancer Test

The US FDA has approved Guardant Health's blood test, Shield, for detecting colorectal cancer (CRC). Shield, previously available as a laboratory-developed test since 2022, is now closer to being Medicare-covered, providing a convenient screening alternative to feces-based tests. This marks the second FDA-approved blood test for CRC screening, following Epigenomics' Epi proColon. Guardant's shares surged 16% following the approval, targeting over 50 million unscreened individuals.

  • #general surgery
  • #pharmacology
  • #general medicine
  • #psych
  • #rheumatology
  • #pathology
  • #radiology
  • #anaesthesia
  • #psychiatry
  • #fmt
  • #emergency medicine
  • #academics
  • #nursing
  • #pharmacy
  • #trichology
  • #andrology
  • #orthopaedics
  • #critical care
  • #dermatology
  • #dentistry
  • #oncology
  • #business
  • #gastroenterology
  • #nephrology
  • #diagnostics
  • #urology
  • #ophthalmology
  • #gynaecology - ivf
  • #pediatrics
  • #neurology
  • #ent
  • #pulmonology
  • #family health
  • #cardiology
  • #endo-diabetology

Like

Save

Share